Christina Nowack

TL;DR: In patients with CKD and type 2 diabetes, treatment with finerenone resulted in lower risks of CKD progression and cardiovascular events than placebo, and the frequency of adverse events was similar in the two groups.

TL;DR: Finerenone demonstrated a dose-dependent reduction in UACR, and among patients with diabetic nephropathy, the addition of finerenone compared with placebo resulted in improvement in the urinary albumin-creatinine ratio.

TL;DR: In patients with HFrEF and moderate CKD, BAY 94-8862 5–10 mg/day was at least as effective as spironolactone 25 or 50mg/day in decreasing biomarkers of haemodynamic stress, but it was associated with lower incidences of hyperkalaemia and WRF.

TL;DR: Finerenone was well tolerated and induced a 30% or greater decrease in NT-proBNP levels in a similar proportion of patients to eplerenone in patients with worsening heart failure and reduced ejection fraction and chronic kidney disease and/or diabetes mellitus.

TL;DR: The HFA‐ESC convened a group of expert heart failure clinical investigators, biostatisticians, regulators, and pharmaceutical industry scientists to evaluate the challenges of defining heart failure endpoints in clinical trials and to develop a consensus framework, and this report summarizes the group's recommendations for achieving common views on heart failureEndpoint selection.